Alpelisib
CAS 1217486-61-7 2 FDA-DMF suppliersSmall Molecule
Overview
Alpelisib is an oral medication used for the treatment of certain types of breast cancer. It works by inhibiting a specific enzyme called PI3K, which is involved in the growth and survival of cancer cells.
Patent & exclusivity (US)
Per the FDA Orange Book (7 approved US products), the latest listed US patent on Alpelisib expires 17 Feb 2037 and exclusivity 4 Apr 2029. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
OncologyBreast CancerPIK3CA-related Disorders
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.